Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05032963 · ClinicalTrials.gov registry record · NA

Neurocognition After Perturbed Sleep

A NA study, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
28
Enrollment target

NCT05032963 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 28 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05032963, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
28 participants
Enrollment target

Study Summary

Individuals with schizophrenia display a wide range of neurocognitive difficulties resulting in functional impairment and disability. Extensive evidence indicates insomnia and sleep disturbances play a substantial role in degrading cognitive functioning. However, the putative impact of insomnia and sleep disturbances on neurocognition and daily functioning has not been investigated in people with schizophrenia. The goal of this study is to characterize sleep in individuals with schizophrenia and quantify its impact on neurocognition and daily functioning.

Interventions

  • BEHAVIORAL Overnight polysomnography examinations

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2021-09-21
Est. Completion 2024-05-31
Phase NA

What the Registry Record Tells You About NCT05032963

The ClinicalTrials.gov registry entry for NCT05032963 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Overnight polysomnography examinations is the first listed.

NCT05032963 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05032963 about?

NCT05032963 is a clinical study titled "Neurocognition After Perturbed Sleep". Individuals with schizophrenia display a wide range of neurocognitive difficulties resulting in functional impairment and disability. Extensive evidence indicates insomnia and sleep disturbances play a substantial role in degrading cognitive functioning. However, the putative impact of insomnia and ...

What is the current status of trial NCT05032963?

This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2021-09-21. Estimated completion is 2024-05-31.

What interventions are being tested in trial NCT05032963?

The interventions under investigation include: Overnight polysomnography examinations (BEHAVIORAL).

Who is sponsoring clinical trial NCT05032963?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.